130 related articles for article (PubMed ID: 23839756)
1. Aldosterone inhibition in patients with heart failure with preserved ejection fraction.
Neil CJ; Singh S; Frenneaux M
JAMA; 2013 Jul; 310(2):204. PubMed ID: 23839756
[No Abstract] [Full Text] [Related]
2. Aldosterone inhibition in patients with heart failure with preserved ejection fraction.
Lund LH; Ståhlberg M
JAMA; 2013 Jul; 310(2):205. PubMed ID: 23839758
[No Abstract] [Full Text] [Related]
3. Aldosterone inhibition in patients with heart failure with preserved ejection fraction.
Milan A; Abram S; Veglio F
JAMA; 2013 Jul; 310(2):204-5. PubMed ID: 23839757
[No Abstract] [Full Text] [Related]
4. Aldosterone inhibition in patients with heart failure with preserved ejection fraction--reply.
Edelmann F; Wachter R; Pieske B
JAMA; 2013 Jul; 310(2):205-7. PubMed ID: 23839759
[No Abstract] [Full Text] [Related]
5. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial.
Edelmann F; Wachter R; Schmidt AG; Kraigher-Krainer E; Colantonio C; Kamke W; Duvinage A; Stahrenberg R; Durstewitz K; Löffler M; Düngen HD; Tschöpe C; Herrmann-Lingen C; Halle M; Hasenfuss G; Gelbrich G; Pieske B;
JAMA; 2013 Feb; 309(8):781-91. PubMed ID: 23443441
[TBL] [Abstract][Full Text] [Related]
6. Defining diastolic heart failure and identifying effective therapies.
Cleland JG; Pellicori P
JAMA; 2013 Feb; 309(8):825-6. PubMed ID: 23443447
[No Abstract] [Full Text] [Related]
7. Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF).
Edelmann F; Schmidt AG; Gelbrich G; Binder L; Herrmann-Lingen C; Halle M; Hasenfuss G; Wachter R; Pieske B
Eur J Heart Fail; 2010 Aug; 12(8):874-82. PubMed ID: 20538867
[TBL] [Abstract][Full Text] [Related]
8. [Spironolactone not effective in diastolic heart failure].
Voors AA
Ned Tijdschr Geneeskd; 2014; 158():A7805. PubMed ID: 25004789
[TBL] [Abstract][Full Text] [Related]
9. Heart failure: Aldosterone antagonism for HFpEF.
Borlaug BA
Nat Rev Cardiol; 2013 May; 10(5):244-6. PubMed ID: 23546445
[No Abstract] [Full Text] [Related]
10. Myocardial Effects of Aldosterone Antagonism in Heart Failure With Preserved Ejection Fraction.
McDiarmid AK; Swoboda PP; Erhayiem B; Bounford KA; Bijsterveld P; Tyndall K; Fent GJ; Garg P; Dobson LE; Musa TA; Foley JRJ; Witte KK; Kearney MT; Greenwood JP; Plein S
J Am Heart Assoc; 2020 Jan; 9(1):e011521. PubMed ID: 31852424
[TBL] [Abstract][Full Text] [Related]
11. [Heart failure with preserved ejection fraction (diastolic heart failure)].
Güder G; Ertl G
MMW Fortschr Med; 2019 May; 161(9):58-65. PubMed ID: 31079412
[No Abstract] [Full Text] [Related]
12. Association of Active and Passive Components of LV Diastolic Filling With Exercise Intolerance in Heart Failure With Preserved Ejection Fraction: Mechanistic Insights From Spironolactone Response.
Kosmala W; Przewlocka-Kosmala M; Marwick TH
JACC Cardiovasc Imaging; 2019 May; 12(5):784-794. PubMed ID: 29248640
[TBL] [Abstract][Full Text] [Related]
13. Effect of spironolactone on diastolic function in hypertensive left ventricular hypertrophy.
Gupta A; Schiros CG; Gaddam KK; Aban I; Denney TS; Lloyd SG; Oparil S; Dell'Italia LJ; Calhoun DA; Gupta H
J Hum Hypertens; 2015 Apr; 29(4):241-6. PubMed ID: 25231508
[TBL] [Abstract][Full Text] [Related]
14. [Effect of spironolactone in patients with heart failure and preserved left ventricular function - TOPCAT study].
Widimský J
Vnitr Lek; 2015 May; 61(5):376-80. PubMed ID: 26075843
[TBL] [Abstract][Full Text] [Related]
15. Diastolic Blood Pressure and Adverse Outcomes in the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) Trial.
Sandesara PB; O'Neal WT; Kelli HM; Topel M; Samman-Tahhan A; Sperling LS
J Am Heart Assoc; 2018 Feb; 7(5):. PubMed ID: 29475874
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone.
Shah AM; Claggett B; Sweitzer NK; Shah SJ; Deswal A; Anand IS; Fleg JL; Pitt B; Pfeffer MA; Solomon SD
Circ Heart Fail; 2015 Nov; 8(6):1052-8. PubMed ID: 26475142
[TBL] [Abstract][Full Text] [Related]
17. Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial.
Lewis EF; Kim HY; Claggett B; Spertus J; Heitner JF; Assmann SF; Kenwood CT; Solomon SD; Desai AS; Fang JC; McKinlay SA; Pitt BA; Pfeffer MA;
Circ Heart Fail; 2016 Mar; 9(3):e001937. PubMed ID: 26962133
[TBL] [Abstract][Full Text] [Related]
18. [2 promising substances for diastolic heart failure].
Einecke D
MMW Fortschr Med; 2012 Sep; 154(15):22. PubMed ID: 22997932
[No Abstract] [Full Text] [Related]
19. Spironolactone and Resistant Hypertension in Heart Failure With Preserved Ejection Fraction.
Rossignol P; Claggett BL; Liu J; Vardeny O; Pitt B; Zannad F; Solomon S
Am J Hypertens; 2018 Mar; 31(4):407-414. PubMed ID: 29228101
[TBL] [Abstract][Full Text] [Related]
20. Effect of Aldosterone Antagonism on Exercise Tolerance in Heart Failure With Preserved Ejection Fraction.
Kosmala W; Rojek A; Przewlocka-Kosmala M; Wright L; Mysiak A; Marwick TH
J Am Coll Cardiol; 2016 Oct; 68(17):1823-1834. PubMed ID: 27765184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
